Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage.

PURPOSE We developed an artificial neural network analysis (ANNA) to predict prostate cancer pathological stage more effectively than logistic regression (LR) based on the combined use of prostate specific antigen (PSA), biopsy Gleason score and pelvic coil magnetic resonance imaging (pMRI) in patients with clinically organ confined disease before radical prostatectomy. MATERIALS AND METHODS In 201 consecutive patients undergoing radical retropubic prostatectomy with pelvic lymphadenectomy the radiological-pathological correlation was evaluated using pMRI. Predictive variables were clinical TNM classification, preoperative serum PSA, biopsy Gleason score and pMRI findings. The predicted results were organ confined vs nonorgan confined disease and lymphatic vs no lymphatic involvement. The predicted ability of ANNA with several parameters in a set of 160 randomly selected test data was compared with that of LR and the Partin tables by area under the receiver operating characteristic curve analysis. RESULTS The overall accuracy of ANNA and LR was 88% and 91%, and 77% and 84% for nonorgan confined and lymphatic involvement, respectively. For nonorgan confined disease and lymph node involvement the area under the curve of ANNA (0.895 and 0.899) was significantly larger than that of LR and the Partin tables (0.722 and 0.751, and 0.750 and 0.733, respectively, p <0.05). Gleason score represented the most influential predictor (relative weight 2.05) of nonorgan confined disease, followed by pMRI findings (1.96), PSA (1.73) and clinical stage (0.89). CONCLUSIONS ANNA is superior to LR for accurately predicting pathological stage. The relative importance of pMRI findings and the usefulness of ANNA for predicting pathological stage in individuals must be confirmed in a prospective trial.

[1]  D. Bostwick Staging prostate cancer--1997: current methods and limitations. , 1997, European urology.

[2]  M W Kattan,et al.  A catalog of prostate cancer nomograms. , 2001, The Journal of urology.

[3]  J. Oesterling,et al.  Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. , 1993, Urology.

[4]  O. Hélénon,et al.  Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. , 2002, Radiology.

[5]  A. Tewari,et al.  The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. , 1995, Urology.

[6]  J. Oesterling,et al.  A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. , 1997, The Journal of urology.

[7]  A. D'Amico,et al.  Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[9]  P. Humphrey Complete Histologic Serial Sectioning of a Prostate Gland with Adenocarcinoma , 1993, The American journal of surgical pathology.

[10]  E. Crawford,et al.  Radical retropubic prostatectomy. , 1983, The Journal of urology.

[11]  Hartwig Huland,et al.  Quantitative biopsy pathology for the prediction of pathologically organ‐confined prostate carcinoma , 2003, Cancer.

[12]  A W Partin,et al.  Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. , 2000, The Journal of urology.

[13]  K. Taari,et al.  Magnetic resonance imaging of clinically localized prostatic cancer. , 1998, The Journal of urology.

[14]  Michael W Kattan,et al.  The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. H. van der Kwast,et al.  Staging prostate cancer , 2000, Microscopy research and technique.

[16]  Shiro Baba,et al.  Artificial neural network analysis for predicting pathological stage of clinically localized prostate cancer in the Japanese population. , 2002, Japanese journal of clinical oncology.

[17]  A. Pantuck,et al.  Review of staging modalities in clinically localized prostate cancer. , 1999, Urology.

[18]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[19]  P. Carroll,et al.  Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils. , 1994, Radiology.

[20]  Richard M. Golden,et al.  Mathematical Methods for Neural Network Analysis and Design , 1996 .